Sunday, November 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· July 18, 2026

Barclays (LSE:BARC) Stock May Trade At A 48% Discount As Returns On Equity Hold

View original at finance.yahoo.com
Barclays (LSE:BARC) Stock May Trade At A 48% Discount As Returns On Equity Hold Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Barclays is undervalued by 47.8% according to the Excess Returns model, implying an intrinsic value of about £9.90 per share

    60% confidence
  • Barclays screens as undervalued in 4 of 6 broader valuation checks, a mixed picture rather than a clear bargain or clearly expensive stock

    60% confidence
  • The implied Excess Return of £0.20 per share suggests Barclays is earning more than its equity charge on a stable basis

    60% confidence

Data points we hold from this source

Barclays · stable book value per share5.80 GBP_per_share
Barclays · stable eps0.69 GBP_per_share
Barclays · stock return 1yr50.7 percent
Barclays · stock return 5yr269.2 percent
Barclays · average return on equity11.81 percent
Barclays · book value per share4.66 GBP_per_share
Barclays · cost of equity0.48 GBP_per_share
Barclays · excess return per share0.20 GBP_per_share
Barclays · intrinsic value per share9.90 GBP_per_share
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Conflicts between sources are checked by an editor before we publish them here.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,959
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,959 facts checked against source5,585 source documents archived
Query this data → isubstrate.com

Working data, not the finished story. This is what our AI has read and extracted from source documents so far. How we source

Barclays (LSE:BARC) Stock May Trade At A 48% Discount As Returns On Equity Hold: Source | Via News | finance.via.news